InnoCare Pharma Ltd. stock analysis
InnoCare Pharma Ltd. (INCPF) Stock Price & Analysis
INCPF Stock Chart & Stats
- Day’s Range
- $1.41 - $1.57
- 52-Week Range
- $1.41 - $2.31
- Previous Close
- $1.51
- Volume
- N/A
- Average Volume (3M)
- 7
- Market Cap
- $2.27B
- Enterprise Value
- $21.04B
- Total Cash (Recent Filing)
- $6.49B
- Total Debt (Recent Filing)
- $2.13B
- Price to Earnings (P/E)
- 12.8
- Beta
- 0.24
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- 0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability Inflection
The sharp revenue increase alongside a substantial swing into profit indicates meaningful commercial traction and operating leverage. If sustained through broader product adoption, this inflection can strengthen internal funding capacity and establish a more durable earnings base.
Liquidity And R&D Capacity
A large liquidity reserve and positive operating cash flow provide resources to fund clinical development, regulatory work, and commercialization without immediate dependence on external financing. Continued R&D investment also supports the pipeline and can extend future growth opportunities.
Commercial Footprint And Pipeline Breadth
An established commercial organization and hospital reach support efficient expansion of approved medicines, while the broad late-stage pipeline creates multiple avenues for future product launches. This combination can reduce dependence on a single development outcome over time.
Bears Say
Orelabrutinib Revenue Concentration
Heavy reliance on orelabrutinib concentrates near-term commercial performance in one product, increasing sensitivity to its growth, market access, and competitive position. Smaller contributions from other medicines mean diversification may take time to materially reduce this exposure.
Clinical Development Timing Risk
Long enrollment periods and delayed readouts postpone potential approvals, launches, and revenue contributions from important programs. Extended development timelines also require sustained investment and leave future growth dependent on execution across multi-year clinical milestones.
Inconsistent Cash Conversion
Positive recent cash flow is encouraging, but weak conversion of reported profit into operating cash can make earnings quality less predictable. The history of negative cash flow indicates that sustained cash generation still needs to be demonstrated across reporting periods.
InnoCare Pharma Ltd. News
INCPF FAQ
What was InnoCare Pharma Ltd.’s price range in the past 12 months?
What is InnoCare Pharma Ltd.’s market cap?
When is InnoCare Pharma Ltd.’s upcoming earnings report date?
How were InnoCare Pharma Ltd.’s earnings last quarter?
Is InnoCare Pharma Ltd. overvalued?
Does InnoCare Pharma Ltd. pay dividends?
What is InnoCare Pharma Ltd.’s EPS estimate?
How many shares outstanding does InnoCare Pharma Ltd. have?
What happened to InnoCare Pharma Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of InnoCare Pharma Ltd.?
What is the TipRanks Smart Score and how is it calculated?
InnoCare Pharma Ltd. Stock Smart Score
Company Description
InnoCare Pharma Ltd.
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jisong Cui
- Employees
- 1,388
- Website
- www.innocarepharma.com
- Address
- Building 8, Beijing, BE, 102206, CN
InnoCare Pharma Ltd. (INCPF) Earnings & Revenues
INCPF Earnings Call
Earnings Call SentimentPositive
The call presents a strongly positive commercial and financial picture in H1 2026: double-digit topline growth (55.5% YoY), a return to profitability (RMB 240 million net profit), strong cash (~RMB 8.4 billion) and positive operating cash flow. R&D investment is ongoing with multiple regulatory approvals/submissions, several Phase III successes, and broad pipeline progress (notably mesutoclax and ADC programs). Key risks are timing and execution of large Phase III programs, dependence on orelabrutinib for near-term revenue, the early-stage nature of many solid tumor programs, BD deal timing uncertainty, and safety/enrollment risks in some autoimmune programs. Overall, the highlights (robust growth, profitability, cash, approvals, and positive late‑stage data) outweigh the lowlights (timing, execution and competitive risks).
View all INCPF earnings summariesINCPF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |
